title: Effects of modulating in vivo nitric oxide production on the incidence and severity of PDE4 inhibitor-induced vascular injury in Sprague-Dawley rats.
abstract: Drug-induced vascular injury (DIVI) is observed in rat mesenteric arterioles in response to treatment with phosphodiesterase-4 inhibitors (PDE4i). However, the mechanisms responsible for causing the characteristic vascular lesions are unclear. Nitrotyrosine (NT) adducts, markers of local nitric oxide (NO) production, have been observed in close proximity to the arterial lesions and in the inflammatory cells associated with DIVI. To determine if NO has a direct role in DIVI, rats were treated with the PDE4i CI-1044 at 10, 20, or 40 mg/kg alone or in combination with the nitric oxide synthase inhibitor L-NAME (60 mg/kg) or the nitric oxide donor SIN-1 (30 mg/kg). Mesenteries were collected and processed for microscopic evaluation. NT formation was evaluated in situ via immunohistochemical staining. Serum nitrite (SN), a marker of in vivo NO production, was measured. Compared with vehicle controls, treatment with CI-1044 alone resulted in dose-related increases in the frequency and severity of vascular injury, SN levels, and NT residues. SIN-1 coadministration caused vascular injury to occur at lower doses of CI-1044, compared with CI-1044 alone, with the overall incidence and severity of injury being greater across all CI-1044-dose groups. Following administration of 20 or 40 mg/kg CI-1044, there were also increases in NT immunoreactivity when SIN-1 was coadministered and significant increases in SN. Conversely, coadministration of L-NAME resulted in marked reduction of injury, NT, and SN when compared with CI-1044 alone. The present study suggests that NO production is closely linked to PDE4i-induced vascular injury.
authors.affiliation: Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Sheth
authors.forename: Bradley E
authors.initials: BE
authors.lastname: Enerson
authors.forename: David
authors.initials: D
authors.lastname: Peters
authors.forename: Michael P
authors.initials: MP
authors.lastname: Lawton
authors.forename: James L
authors.initials: JL
authors.lastname: Weaver
mesh_terms: D000818:Animals; D001381:Azepines / Q000009:adverse effects; D015415:Biomarkers / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000009:adverse effects; D007150:Immunohistochemistry; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects / Q000473:pathology; D008981:Molsidomine / Q000031:analogs & derivatives / Q000378:metabolism; D019331:NG-Nitroarginine Methyl Ester / Q000009:adverse effects; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009573:Nitrites / Q000097:blood; D058988:Phosphodiesterase 4 Inhibitors / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014443:Tyrosine / Q000031:analogs & derivatives / Q000032:analysis; D057772:Vascular System Injuries / Q000139:chemically induced*
chemical_list: D001381:Azepines; D015415:Biomarkers; D004791:Enzyme Inhibitors; D009573:Nitrites; D058988:Phosphodiesterase 4 Inhibitors; D009536:Niacinamide; D009569:Nitric Oxide; C002744:3-nitrotyrosine; D014443:Tyrosine; C002385:linsidomine; D008981:Molsidomine; D019001:Nitric Oxide Synthase; C418118:CI 1044; D019331:NG-Nitroarginine Methyl Ester